8 years after its OK, Eisai yanks its flailing obesity drug from the market after FDA flagged higher cancer rate
CAMELLIA-TIMI 61 was supposed to be the trial that would resolve the FDA’s concerns about Belviq as Eisa investigators showed that the weight loss drug didn’t increase incidences of cardiovascular events. Instead, it unearthed new issues that’s now led to its demise.
At regulators’ request, Eisai said it’s withdrawing both the original and extended release version of Belviq from the US market, where it earned a little more than $28 million from April to December 2019.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.